drugset / Trial / NCT05349266
Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B-NHL After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase I, single center study to assess the efficacy and safety of ThisCART19A in adult with Non-Hodgkins Lymphoma in China.
Timeline
- Start
- 2022-03-18
- Primary completion
- 2024-03-30
- Completion
- 2024-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ThisCART19A | Cell therapy | 2 cells/kg | — |
| Subject | ThisCART19A | Cell therapy | 3 cells/kg | — |
| Subject | ThisCART19A | Cell therapy | 4 cells/kg | — |